PEMBRO-RT II期研究显示,SBRT后使用免疫检查点抑制剂后,对照组12周的应答率为18%,试验组12周的应答率为36%(p=0.07)。虽然该研究没有达到预先确定的疗效终点,但在PD-L1阴性亚组中观察到PFS和总生存期获益,这表明SBRT可能对治疗冷肿瘤有效。 同时各种新型疗法CAR-T、肿瘤疫苗、新型免疫检查点抑制剂(TIGIT抑制剂...
Methods Assessment of key maintenance PARPis in platinum-sensitive ovarian cancer was conducted on the following phase III RCTs: olaparib (SOLO1, SOLO2); rucaparib (ARIEL3); and niraparib (NOVA). The primary outcomes for multiple-treatment meta-analysis were efficacy (HRs for PFS) and ...
The ultimate goal in cancer treatment is to cure the disease, but when this is not possible, the goal becomes providing the best palliation. The most important outcomes of treatment are overall survival (OS) and disease-free survival (DFS). However, longer progression-free survival (PFS), ...
声明: 本网站大部分资源来源于用户创建编辑，上传，机构合作，自有兼职答题团队，如有侵犯了你的权益，请发送邮箱到feedback@deepthink.net.cn 本网站将在三个工作日内移除相关内容,刷刷题对内容所造成的任何后果不承担法律上的任何义务或责任
Venetoclax is a first-in-class, oral, selective BCL-2 inhibitor (BH3-only mimetic). The drug is approved in numerous countries, including those of the EU and in the USA, for the treatment of adults with relapsed or refractory (RR) CLL.
No statistically significant difference was found in overall survival associated with nPSA at this point. nPSA is a strong independent predictor of freedom from PSA failure and PFS in patients with low and intermediate-risk localized prostate cancer treated with RT alone. Longer follow-up and larger...
Although a majority of biologists are convinced that a mass extinction is underway on earth today, the human history with direct observatory data is too short to predict its future trends. At least five mass extinctions occurred during the Phanerozoic Eon, causing the rapid extinction of at least...
Researchers developed a pan-immune-inflammation–based nomogram to accurately predict overall survival (OS) and progression-free survival (PFS) in patients with epithelial ovarian cancer September 21st 2024 First-Line Combo Yields Strong Results in Advanced Sarcoma Maggie L. Shaw The phase 1/2 SAINT...
Transcript:Maciej Mrugala, MD, PhD, MPH: Glioblastoma is a primary brain tumor that originates, typically, in the brain structures. It is in that way different from other primary solid tumors, let’s say breast cancer or melanoma, that can potentially travel to the brain. This means that ...
The 2023 system with molecular classification was associated with PFS and overall survival (p<0.001 and p=0.038, respectively). Conclusion: The 2023 FIGO staging system for endometrial cancer subdivided stages I and II compared to the 2009 system. The 2023 FIGO staging system...